Sequelae of metrizamide myelography in 200 examinations.
Twenty pediatric and 180 adult patients underwent myelography using metrizamide (Amipaque). All patients were examined and interviewed before and after the studies. New or exacerbated symptoms attributed to metrizamide myelography were graded according to severity. After the procedure, 51 of 200 patients were unchanged from baseline. Headache was the most common complaint, with an overall incidence of 62%. Nausea and/or vomiting occurred in 38%. Back or leg pain, neck stiffness, temperature elevation, and a variety of less common manifestations were also observed. The incidence of sequelae was higher than in comparable Scandinavian studies with this contrast medium.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D005334:Fever / Q000139:chemically induced; D005500:Follow-Up Studies; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007223:Infant; D008297:Male; D008793:Metrizamide / Q000009:adverse effects*; D008875:Middle Aged; D009192:Myelography; D009325:Nausea / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D008793:Metrizamide